Gastric cancer in Alaska Native people: A cancer health disparity

Table 3 Univariate analysis of Alaska Native gastric cancer patients to identify variables associated with overall survival

	HR1	95%CI	P2 value
Age, ≥ 55 yr vs < 55 yr	0.73	0.49-1.07	0.11
Sex, male vs female	0.86	0.59-1.27	0.45
Geographical Region			0.53
North	1.00
Interior	0.99	0.50-1.96
Southwest	0.68	0.42-1.11
Southcentral	1.00	0.61-1.62
Southeast	0.65	0.15-2.69
Signet ring, present or absent	0.78	0.52-1.17	0.22
Diffuse vs intestinal	1.01	0.68-1.49	0.97
Anatomic site			0.07
Noncardia Cardia	1.00
Cardia3	1.10	0.66-1.84
Overlap/NOS	1.74	1.08-2.81
Grade			0.22
Poorly differentiated	1.00
Well/moderately	0.70	0.66-1.84
Unknown	0.82	0.37-1.84
AJCC Stage			< 0.0001
I	1.00
II	1.42	0.74-2.75
III	1.67	0.79-3.54
IV	4.91	2.80-8.61
Treatment4			< 0.0001
Chemo	1.00
None	2.07	1.29-3.32
Neoadjuvant, surgery	0.23	0.12-0.45
Surgery only	0.29	0.14-0.61
Surgery, adjuvant	0.27	0.13-0.59
Neoadjuvant, surgery, adjuvant	0.15	0.06-0.39
No. of nodes examined, ≥ 15 vs < 155 nodes3	0.37	0.19-0.75	< 0.0001
Blood Type			0.04
A+	1.00
AB+	0.88	0.42-1.82
B+	1.72	0.76-3.96
O+	1.78	1.05-3.01
Unknown	2.35	1.24-4.45
Multiple primaries, yes vs no	0.73	0.45-1.17	0.22
Tobacco			0.51
Yes	1.00
None	0.83	0.49-1.42
Chew/Iqmik	0.78	0.31-1.95
Former user6	1.26	0.80-1.97
Gastric ulcer, yes vs no	1.02	0.67-1.54	0.93
Chronic Gastritis, yes vs no	0.62	0.39-0.98	0.04
H. pylori, tumor positive vs negative	0.90	0.61-1.34	0.62
GERD, yes vs no	0.75	0.51-1.13	0.17

¹Univariate analysis was performed using Kaplan-Meier analysis model and log-rank test;

²Bold type indicates statistical significance (P < 0.05);

³Cardia includes gastroesophageal junction and cardia gastric cancers;

⁴Neoadjuvant and adjuvant treatments include chemotherapy and chemoradiation regimens based on NCCN guidelines;

⁵Patients that had a resection were included in analysis;

⁶Patients discontinued smoking before time of diagnosis. HR: Hazard ratio; CI: Confidence interval; AJCC: American Joint Committee on Cancer; Chemo: Chemotherapy; H. pylori: Helicobacter pylori; GERD: Gastroesophageal reflux disease.